VP45.21: Clinical correlation of severe and non‐severe infection by SARS‐CoV2 in pregnant women

Abstract

To correlate the characteristics and clinical course in pregnant women with severe and non-severe infection by SARS-CoV2 in General Hospital of Mexico. Observational and descriptive study of clinical features, laboratory and cabinet studies of pregnant with SARS-CoV2 who requested obstetric care at the General Hospital of Mexico, from April to May 2020. It was used to graph graphpad prism 8. In General Hospital of Mexico April-May 2020, 16 patients confirmed for SARS-CoV2 by rt-PCR. Symptoms: cough 13/16 (81.2%), fever, myalgia or arthralgia and dyspnea 9/16 (56.2%), pharyngodynia 7/16 (43.7%), fatigue 6/16 (37.5%). Morbidities: obesity 6/16 (37.5%), gestational diabetes 4/16 (25%), no morbidity 4/16 (25%), gestational hypertension 2/16 (12.5%). Chest x-ray: polished glass 9/16 (56.2%), parenchymal consolidation 7/16 (43.7%) and 7/16 (43.7%) no radiography was performed. Chest tomography 3/16 parenchymal consolidation and polished glass. Severe infection 2/16 (12.5%) and non-severe infection 9/16 (56.2%), and a subgroup of patients who required ambulatory management in 5/16 (31.2%). 2/16 required invasive mechanical ventilation (12.5%), presented sepsis, admission to the intensive care unit. 9/16 (56.2%) without oxygen, 4/16 (25%) nasal tips, 2/16 (12.5%) with invasive mechanical ventilation and 1/16 (6.2%) with a reservoir mask. 3/16 showed clinical improvement during hospitalisation and fetal well-being corroborated by Doppler flowmetry, with hospital discharge and telephone follow-up. Caesarean section 6/8 (75%), 2/8 vaginal delivery (25%). In 6/7 Caesarean sections was oligohydramnios. Neonates 8/8 (100 %) of newborns with rt-PCR negative for SARS-VOC-2 and without reported neonatal mortality. Pregnant women are among vulnerable groups to complicate before a respiratory infection, therefore it is important to identify clinical characteristics and morbidities that complicate the SARS-CoV2 infection, which will allow timely diagnosis and multidisciplinary treatment balancing the clinical course of COVID-19 disease with perinatal results.